| 2.37 Data as of May 24 | -0.01 / -0.42%Today’s Change | 2.35 Today|||52-Week Range 6.33 | -3.66% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Biotechnology | MARKET CAP $65.9M |
Company Description
Maxygen, Inc. is a biotechnology company. It is focused on the potential further development of its MAXY-G34 product, a next-generation pegylated, granulocyte colony stimulating factor, G-CSF, for the treatment of chemotherapy induced neutropenia and acute radiation syndrome. G-CSF is a natural protein that functions by stimulating the body's bone marrow to produce more white blood cells. The company was founded on May 7, 1996 and is headquartered in San Mateo, CA.
Employees

Shareholders
| Other institutional | 40.18% |
| Individual stakeholders | 27.52% |
| Mutual fund holders | 21.45% |
Top Executives
| James R. Sulat, MBA | Director, Chief Executive & Financial Officer |
| Grant Yonehiro, MBA, CFA | Senior Vice President |
| Adriann Poat | Head-Media Relations |
| John M. Borkholder | Secretary & General Counsel |